572 related articles for article (PubMed ID: 18006253)
21. Efficacy of two canine parvovirus vaccines for inducing seroconversion in Rottweiler and Doberman pinscher pups with various levels of maternally derived antibodies.
Coyne MJ
Vet Ther; 2000; 1(1):35-42. PubMed ID: 19757563
[TBL] [Abstract][Full Text] [Related]
22. Intranasal vaccination of pups in the presence of maternally derived antibodies to canine parvovirus (CPV). Evaluation of minimal immunizing dose.
Buonavoglia C; Cavalli A; Tempesta M; Voight V; Buonavoglia D; Corrente M; Sagazio P
New Microbiol; 1995 Oct; 18(4):371-5. PubMed ID: 8590389
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the humoral immune response induced by vaccination for canine distemper and parvovirus: a pilot study.
Vila Nova B; Cunha E; Sepúlveda N; Oliveira M; São Braz B; Tavares L; Almeida V; Gil S
BMC Vet Res; 2018 Nov; 14(1):348. PubMed ID: 30445957
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Challenges in Canine Parvovirus 2c in Vaccine Failure Cases.
Yip HYE; Peaston A; Woolford L; Khuu SJ; Wallace G; Kumar RS; Patel K; Ahani Azari A; Akbarzadeh M; Sharifian M; Amanollahi R; Jafari Jozani R; Khabiri A; Hemmatzadeh F
Viruses; 2020 Sep; 12(9):. PubMed ID: 32899378
[TBL] [Abstract][Full Text] [Related]
25. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
[TBL] [Abstract][Full Text] [Related]
26. Vaccination at different anatomic sites induces different levels of the immune responses.
Jin H; Xu Y; Shi F; Hu S
Res Vet Sci; 2019 Feb; 122():50-55. PubMed ID: 30453180
[TBL] [Abstract][Full Text] [Related]
27. Passive protection of dogs against clinical disease due to Canine parvovirus-2 by specific antibody from chicken egg yolk.
Van Nguyen S; Umeda K; Yokoyama H; Tohya Y; Kodama Y
Can J Vet Res; 2006 Jan; 70(1):62-4. PubMed ID: 16548334
[TBL] [Abstract][Full Text] [Related]
28. [Canine parvovirus: recent knowledge of the origin and development of a viral pathogen].
Truyen U
Tierarztl Prax; 1994 Dec; 22(6):579-84. PubMed ID: 7716757
[TBL] [Abstract][Full Text] [Related]
29. Canine parvovirus vaccination.
Atkinson M
Vet Rec; 2006 Dec 23-30; 159(26):895; author reply 895-6. PubMed ID: 17189604
[No Abstract] [Full Text] [Related]
30. Antibodies to parvovirus, distemper virus and adenovirus conferred to household dogs using commercial combination vaccines containing Leptospira bacterin.
Taguchi M; Namikawa K; Maruo T; Lynch J; Sahara H
Vet Rec; 2010 Dec; 167(24):931-4. PubMed ID: 21262693
[TBL] [Abstract][Full Text] [Related]
31. Are licensed canine parvovirus (CPV2 and CPV2b) vaccines able to elicit protection against CPV2c subtype in puppies?: A systematic review of controlled clinical trials.
Hernández-Blanco B; Catala-López F
Vet Microbiol; 2015 Oct; 180(1-2):1-9. PubMed ID: 26249827
[TBL] [Abstract][Full Text] [Related]
32. Evolution of canine parvovirus--a need for new vaccines?
Truyen U
Vet Microbiol; 2006 Oct; 117(1):9-13. PubMed ID: 16765539
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the natural immunity in pups inoculated with a modified-live canine parvovirus type 2b (CPV-2b) strain.
Pratelli A; Altamura M; Buonavoglia D; Pepe M; Tafaro A; Lembo A; Cirone F; Tempesta M; Jirillo E; Buonavoglia C
Immunopharmacol Immunotoxicol; 2000 Aug; 22(3):451-64. PubMed ID: 10946825
[TBL] [Abstract][Full Text] [Related]
34. Opposing views of revaccination strategies.
Palmquist R
J Am Vet Med Assoc; 2000 Dec; 217(12):1789-91. PubMed ID: 11132877
[No Abstract] [Full Text] [Related]
35. Efficacy of vaccination at 4 and 6 weeks in the control of canine parvovirus.
De Cramer KG; Stylianides E; van Vuuren M
Vet Microbiol; 2011 Apr; 149(1-2):126-32. PubMed ID: 21111542
[TBL] [Abstract][Full Text] [Related]
36. Maternally-derived antibodies in pups and protection from canine parvovirus infection.
Decaro N; Campolo M; Desario C; Elia G; Martella V; Lorusso E; Buonavoglia C
Biologicals; 2005 Dec; 33(4):261-7. PubMed ID: 16168665
[TBL] [Abstract][Full Text] [Related]
37. Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins.
Pardo MC; Bauman JE; Mackowiak M
Am J Vet Res; 1997 Aug; 58(8):833-6. PubMed ID: 9256965
[TBL] [Abstract][Full Text] [Related]
38. Compatibility of a bivalent modified-live vaccine against Bordetella bronchiseptica and CPiV, and a trivalent modified-live vaccine against CPV, CDV and CAV-2.
Jacobs AA; Bergman JG; Theelen RP; Jaspers R; Helps JM; Horspool LJ; Paul G
Vet Rec; 2007 Jan; 160(2):41-5. PubMed ID: 17220520
[TBL] [Abstract][Full Text] [Related]
39. Canine parvovirus infection potentiates canine distemper encephalitis attributable to modified live-virus vaccine.
Krakowka S; Olsen RG; Axthelm MK; Rice J; Winters K
J Am Vet Med Assoc; 1982 Jan; 180(2):137-9. PubMed ID: 7061309
[TBL] [Abstract][Full Text] [Related]
40. Serologic response of pups to the low-passage, modified-live canine parvovirus-2 component in a combination vaccine.
O'Brien SE
J Am Vet Med Assoc; 1994 Apr; 204(8):1207-9. PubMed ID: 8014088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
